Wolters Kluwer


18/06/26 -"We have slightly cut our DCF-derived target price after the publication of a study in Nature Medicine (https://www.nature.com/articles/s41591-026-04431-5) suggesting that clinical decision support ..."

Pages
60
Language
English
Published on
18/06/26
You may also be interested by these reports :
18/06/26
We have slightly cut our DCF-derived target price after the publication of a study in Nature Medicine ...

18/06/26
Informa surprised on the upside on both academic research and Live B2B Events, probably benefiting from an AI boost. This performance is notable ...

17/06/26
In our last teaser, we focused on the laborious digital transition of ITV (SELL; UK), facing increasing competition from major US global streaming ...

09/06/26
Media like Software has been pilloried by AI buffs. This disastrous moment seems to have found a floor since last March. The going is hesitant and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO